As the first and only commercial supplier of copper-67, Iotron Medical is committed to improving the quality and accessibility of this radioisotope for the radiopharmaceutical community.
Copper-67 is a proven and effective radioisotope for theranostics, particularly when paired with copper-64. This “perfect paring” delivers key advantages over other commonly used isotopes, including:
- Identical in-vivo behavior (imaging and therapy)
- Patient dose optimization (personalized medicine)
- Optimum half-life for small molecules
- Convenient off-site central manufacturing
- No reliance on nuclear reactors for production
Through our partnership with Canadian Isotope Innovation Corp., Iotron Medical is supplying copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostics.
For more information, please visit www.copper67.com.